New Delhi, Aug 8 (PTI) The Initial Public Offer (IPO) of Concord Biotech was subscribed 24.86 times on the closing day of subscription on Tuesday.

The Rs 1,550.59 crore initial share sale received bids for 36,42,83,240 shares against 1,46,50,957 shares on offer, according to NSE data.

Also Read | Gaurav Gogoi on Manipur Issue: No-Confidence Motion Not for Numbers But for Justice for Manipur, Says Congress MP.

The category for Qualified Institutional Buyers (QIBs) received 67.67 times subscription, the portion for non-institutional investors was subscribed 16.99 times and Retail Individual Investors (RIIs) part 3.78 times.

The IPO of 20,925,652 equity shares had a price range of Rs 705-741 a share.

Also Read | PM Narendra Modi Describes INDIA as 'Ghamandia', Says Opposition Brought No-Confidence Motion To Test Confidence of Their Own Allies.

The IPO of the Ahmedabad-based company was entirely an Offer For Sale (OFS).

Rare Enterprises-backed Concord Biotech on Thursday said it collected Rs 465 crore from anchor investors.

Concord is among leading manufacturers of fermentation-based biopharmaceutical active pharmaceutical ingredient (API), focused on niche segments such as immunosuppressant, oncology, anti-fungal and anti-bacterial.

The company, which currently has 23 API products, has three manufacturing facilities at Valthera, Dholka, and Limbasi, in Gujarat.

Kotak Mahindra Capital Company, Citigroup Global Markets India and Jefferies India were the managers to the offer.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)